ALK and non-small cell lung carcinoma: One analysis of the CNS data for patients with measurable IMD who received alectinib hydrochloride for anaplastic lymphoma kinase (ALK)–positive NSCLC reported a CNS ORR of 64.0% (95% CI, 49.2%-77.1%; 32 of 50 patients).45 Another study46 in patients receiving brigatinib for ALK-positive NSCLC reported a CNS ORR of 67% (95% CI, 41%-87%; 12 of 18 patients).